Failure to THRIVE: the end for niacin?

Nature Reviews Cardiology

Volumn 10, Issue 5, 2013, Pages 246-247

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; PLACEBO; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; INDOLE DERIVATIVE; LIPID; MK-0524;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG ANTAGONISM; DRUG MARKETING; DRUG MEGADOSE; DYSLIPIDEMIA; HUMAN; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; BLOOD; DRUG COMBINATION; NOTE; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; NIACIN; TREATMENT OUTCOME;

EID: 84876896447     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.48     Document Type: Review

References (10)

1. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975).
2. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/eht055.
3. O'Riordan, M. "If not dead, not healthy": Niacin full results in HPS2-THRIVE aired at ACC. Theheart.org [online], http://www.theheart.org/ article/1515533.do (2013).
4. The AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
5. The ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
6. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
7. Vogt, A., Kassner, U., Hostalek, U. & Steinhagen-Thiessen, E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: The NAUTILUS study. Curr. Med. Res. Opin. 22, 417-425 (2006).
8. Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 305, 2556-2564 (2011).
9. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
10. Maher, V. M. et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274, 1771-1774 (1995).